NEW YORK (GenomeWeb News) – Natera today announced a US distribution deal with pathology services provider ProPath for Natera's Panorama non-invasive prenatal screening test.
The test uses a blood draw to detect trisomy 21, 18, and 13, as well as monosomy X, triploidy, and sex chromosome aneuploidies. It employs Natera's algorithm called Next Generation Aneuploidy Testing Using SNPs to analyze cell-free DNA from both the mother and the fetus.
Natera also has deals with Quest Diagnostics, Bio-Reference Laboratories, and Arup Laboratories to offer Panorama in the US. In December, New York issued a permit for Natera's CLIA laboratory, allowing the company to offer its preconception and prenatal tests, including Panorama, to expecting parents in the state.
Financial and other terms of the ProPath deal were not disclosed.